

Anti- Ehrlichia properties of the dichloromethane extract of *Ageratum conyzoides*

Carla Janaina Rebouças Marques do Rosário

Universidade Estadual do Maranhão <https://orcid.org/0000-0002-7682-8141>

Claudia Quintino da Rocha

Universidade Federal do Maranhao

Daniel Moura de Aguiar

Universidade Federal de Mato Grosso

Cristian Alex Aquino Lima

Universidade Estadual do Maranhao

Daniella Patrícia Brandão Silveira

Universidade Federal do Maranhao

José Antônio Costa Leite

Universidade Federal do Maranhao

Denise Fernandes Coutinho

Universidade Federal do Maranhao

Ferdinan Almeida Melo (✉ ferdinanalmeida.uema@gmail.com)

<https://orcid.org/0000-0001-6111-3672>

Original article

Keywords: Ehrlichia canis, alternative therapies, herbal medicine, "catinga-de-bode", DH82 cells, lignans

Posted Date: February 12th, 2020

DOI: <https://doi.org/10.21203/rs.2.23379/v1>

License:   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Ehrlichia canis is an intracellular bacterium that infects hematopoietic cells. It is the causative agent of canine monocytic ehrlichiosis (CME). The disease may be acute, subclinical, or chronic, and is treated with tetracyclines including doxycycline. However, this class of tetracyclines may cause several side effects due to prolonged treatment. Bacterial resistance to antimicrobials has been extensively reported.

The present study aimed to assess the anti- *Ehrlichia* activity of the dichloromethane extract (DCM) of *Ageratum conyzoides* L. on *Ehrlichia*- infected DH82 cells. For this purpose, the DCM extract of *A. conyzoides* collected in the municipality of São Luís, State of Maranhão (MA), northeast Brazil, was obtained from the aerial parts of the plant by exhaustive percolation in H₂O- CH₂Cl₂ (2:8) and subsequent extraction of the chemical compound. The chemical composition of these samples was investigated. The anti- *Ehrlichia* properties of *A. conyzoides* were confirmed in *Ehrlichia*- infected DH82 cells at a concentration of 200 µg.mL⁻¹ of its DCM extract. The results of the treatments were evaluated at 18h and 36h after the insertion of the treatments evaluated with *A. conyzoides*.

Based on the results of the chemical analysis of the samples, we may attribute these antirickettsial properties to the compounds from the lignan family that are found in this medicinal plant .

Introduction

Ehrlichia spp. is an obligate intracellular bacterial pathogen that parasitizes hematopoietic cells (leukocytes). This rickettsial organism infect a wide range of mammalian hosts including dogs, cats, cattle, horses, and humans (Bogićević et al. 2017). Canine monocytic ehrlichiosis (CME) is caused by the bacterium *Ehrlichia canis* and has the ixodid tick *Rhipicephalus sanguineus* (common name: brown dog tick) as its main vector (Dagnone et al. 2001). The disease may be acute, subclinical, or chronic.

In the acute phase of the disease, clinical signs include depression, lethargy, anorexia, pyrexia, lymphadenopathy and splenomegaly, and weight loss. Affected animals may exhibit bleeding especially petechiae and ecchymoses on the skin and mucous membranes and occasional epistaxis (Waner and Harrus 2000; Sousa et al. 2010). The subclinical phase of the disease consists of variable, persistent thrombocytopenia, leukopenia, and anemia in the absence of clinical signs (Varela 2003; Breitschwerdt 2004; Sousa et al. 2010). The chronic phase of canine monocytic ehrlichiosis may be severe and present as a fatal hemorrhagic syndrome due to bone marrow failure (Mylonakis et al. 2003).

The drug of choice for the treatment of the disease in all its phases is doxycycline for 28 days (Tilley et al. 2003). However, the drugs of the tetracycline group may have some undesired effects when administered for prolonged periods of time. The most notable toxic effects of tetracyclines are observed in the bone and teeth. It causes a delay in bone formation and yellowish discoloration of teeth (Damaso 1990). Tetracycline bone toxicity results from neuromuscular blockade which is probably produced by the chelation of calcium ions (Goodman and Gilman 1990) and direct action on the mechanism of bone

absorption and resorption by osteoclasts (Donahue et al. 1992) interfering with the deposition of calcium in bone tissue (Van Linthoudt et al. 1991).

In addition, photosensitivity manifested by hyperpigmentation, erythema, and ultimately skin ulceration is frequently associated with tetracycline therapy (Cunha 2001). The most frequent clinical signs observed in patients treated with tetracyclines are digestive and include nausea, vomiting, diarrhea, abdominal pain, gastritis, and enterocolitis (Damaso 1990; Guglielmo and Jacobs 2001; Saucedo 2003; Torres 2000; Workowski 2000; Zimmerman 2000). This drug is able to cross the placental barrier and is therefore contraindicated during pregnancy. Tetracycline should not be given to puppies (Guglielmo and Jacobs 2001).

According to González-Lamothe et al. (2009), the products of secondary metabolism accumulated by plants can act as "potentiators of antibacterial activity", favoring the activity of antibiotics whose action is limited by multidrug resistance mechanisms developed by microorganisms; or as "virulence attenuators", adapting the host's immune system response to infection.

Ageratum conyzoides L. is present in the vast majority of the Brazilian states. Common names for this plant are "mentrasto" and "catinga-de-bode". It occurs mainly in anthropic areas and in plantations (Kissmann and Groth 1999). This ethnomedicinal plant has anti-inflammatory, analgesic, antidiarrheal, and antimicrobial properties (Cimanga et al. 2014; Prajapati et al. 2014). Its anti-Leishmania activity was recently reported in the literature (Teixeira et al. 2014). Compounds found in *Ageratum conyzoides* L. (terpenes, monoterpenes, sesquiterpenes, quinolones, phenolic compounds and flavonoids) have antimicrobial activity well described in literature, methanolic extracts have already shown to be effective against *Escherichia coli*, *Klebsiella oxytoca*, *Proteus mirabilis*, *Salmonella typhimurium*, *Staphylococcus aureus* and *Shigella flexneri* (Samy et al. 2013). Studies have also confirmed the efficacy of dichloromethane extracts against bacteria *Staphylococcus aureus* *Escherichia coli* (Kanyanga et al. 2014). In addition to the capacity to inhibit the replication of intracellular microorganisms (Singh et al. 2016). The present study aimed to analyze the anti-Ehrlichia activity of the dichloromethane extract (DCM) of *Ageratum conyzoides* L. in Ehrlichia-infected DH82 cells.

Materials And Methods

Plant material

The plant species *Ageratum conyzoides* L. was cultivated and collected at the Berta Langes de Morretes Medicinal Herb Garden of the Federal University of Maranhão (UFMA), municipality of São Luís, State of Maranhão (MA), northeast Brazil (2°33'13.5"S and 44°18'20.8"W) in July 2017 (rainy season), according to the method published in the Brazilian Pharmacopeia (ANVISA 2010). The plant was herborized and identified, and a sample (voucher specimen - MAR 9099) is deposited at the Herbarium of Maranhão (MAR), located in Federal University of Maranhão, Brazil.

The access was registered under the ID number ADBBA07 in the National System of Management of Genetic Heritage and Associated Traditional Knowledge. The collection did not involve endangered or protected species.

Method to obtain the extract and the extract of the plant

A total of 1.7 kg of the aerial parts of *Ageratum conyzoides* L. was collected in the early hours of the morning. Samples were dried at room temperature (25 °C) for a 7-day period. An infrared moisture analyzer (GEHAKA IV 2500) was used to measure the plant moisture and calculate the yield. Shortly after that, the dry aerial parts of *A. conyzoides* were crushed in a mechanical turbolizer. The exhaustive percolation in H₂O- CH₂Cl₂ (2:8) was the extraction method used in this study. Percolation was carried out at room temperature (25 °C) and protected from light. The extractor liquid was completed every 24h corresponding to a total of 72h until the plant material exhaustion was finished. These compounds were evaporated to dryness under vacuum at approximately 40 °C. Shortly after that, the specimen was ultra-refrigerated at -80 °C to be lyophilized and to obtain the dry extract.

Analysis of the Extract of *Ageratum conyzoides* L. by High Performance Liquid Chromatography (HPLC) with ultraviolet detection

After cleaning up the extract, the sample was analyzed by HPLC using a Shimadzu® chromatograph (Shimadzu Corp., Kyoto, Japan) consisting of a solvent injection module with a binary pump and UV detector -Vis (SPA-10A). The column used was a Luna 5 µm C18 100 A (150 µm x 4.6 µm). The elution solvents used were elution solvent A (water + 0.01% formic acid) and elution solvent B (methanol + 0.01% formic acid). Samples were eluted according to the following exploratory gradients: 5% to 100% B in 60 min and 100% to 100% in 60 to 70 min. The flow rate was 1 mL/min, and the column temperature was 20 °C. The injection volume of the sample was 20 µL. Data were collected and processed using the LC Solution software (Shimadzu). In this study, baseline separation for the major components of the sample was obtained in a 70-min chromatographic run and evaluated at a 254 nm wavelength.

Characterization of the components of *Ageratum conyzoides* L. by liquid chromatography-mass spectrometry (LC-MS) and electrospray ionization mass spectrometry (FIA-ESI-MS)

Characterization of the compounds extracted from *Ageratum conyzoides* L. was carried out at the Institute of Biosciences, São Paulo State University (Unesp), São Vicente, SP, southeast Brazil. By infusing the samples directly into a mass spectrometer with an ion-trap linear analyzer (Thermo Scientific LTQ XL) equipped with an electrospray (ESI) in negative mode (Thermo, San Jose, CA, USA). A stainless-steel capillary tube at 280 °C, a spray voltage of 5.00 kV, a capillary voltage of -90 V, and a -100 V tube lenses at a flow of 5 µL/min were used in this procedure. Samples were infused into the mass spectrometer from the HPLC system in which samples were analyzed online by ESI-MS in negative mode and with an associated UV detector. The mass spectra data were obtained in the same Fleet LCQ mass spectrometer from Thermo Scientific® with direct insertion of the sample device via continuous flow injection analysis (FIA). Samples were ionized with an ESI source. Fragmentations were obtained in multiple stages (MSⁿ)

in an ion trap (IT)-type interface. The negative mode was used for the generation and analysis of all spectra. The experimental conditions were the following: capillary voltage of -35 V, spray voltage -5000 V, capillary temperature 350 °C, carrier gas N_2 and flow 60 (arbitrary units). The track acquisition was in a mass range of m/z 100 – 2000 with two or more sweep events performed simultaneously in the spectrum. Compounds were identified by comparing between data from literature and fragmentation patterns.

Culture of *Ehrlichia canis*-DH82 cells

The *Ehrlichia canis* strain was obtained from the 35th passage of *E. canis* of the Cuiabá #1 isolate which belongs to the collection (library) of Rickettsiae and *Ehrlichia* from the Laboratory of Virology and Rickettsioses of the School of Veterinary Medicine of the Federal University of Mato Grosso (FMVZ/UFMT), Cuiabá, MT, central-west Brazil. This rickettsial strain multiplied in DH82 cell monolayers (ATCC number: CRL-10389) and was maintained at 37 °C and 5% CO_2 .

The access was registered under the number A9463BB in the National System of Management of Genetic Heritage and Associated Traditional Knowledge according to art. 41 of Decree N°. 8772/2016 of the Ministry of the Environment in Brazil.

DH82 cells (Canine Histiocyte: ATCC in CRL-10389) grew in Dulbecco's Modified Eagle's (DMEM) medium (Sigma Chemical Co., St. Louis, MO, USA), plus 5% fetal serum of calf (HyClone Laboratories, Logan, Utah, USA) and culture bottle of 25 cm² at 37 °C and 5% CO_2 as recommended by Aguiar et al. (2007). The rate of *E. canis* infection was determined by screening Diff-Quik stained cell monolayer smears (Laborclin, Pinhais, PR, Brazil) under the light microscope.

When an infection rate of 70% was detected, the cells were resuspended in the same medium and the cell suspension was centrifuged at $4,000$ g for 5 min. The experiments were run in 24-well culture plates at 37 °C and 5% CO_2 . The infection rate was standardized at $3,000$ cells per well and 70% of infected cells (Aguiar et al. 2007).

Anti-*Ehrlichia* assay

The assays were performed in the IC₅₀ determination of the treatments studied against *E. canis* was determined from the test concentrations of 25 $\mu\text{g.mL}^{-1}$, 50 $\mu\text{g.mL}^{-1}$, 100 $\mu\text{g.mL}^{-1}$, 200 $\mu\text{g.mL}^{-1}$, 300 $\mu\text{g.mL}^{-1}$, 400 $\mu\text{g.mL}^{-1}$ and 500 $\mu\text{g.mL}^{-1}$ in cell monolayers DH82 infected with *E. canis* at a 70% infection rate, cell quantities were standardized at $3,000$ cells / well, in 24-well plates, assays were performed in triplicate, where treatment control used spun doxycycline $1\mu\text{g.mL}^{-1}$, according to the package insert, and as a control of bacterial culture, wells treated only with distilled water. The protocol used to determine the antimicrobial effect of the test treatments was an adaptation by Rolain et al. (1998) and Rolain et al. (2002).

Cell viability analyses were performed using the trypan blue assay (Trypan blue exclusion test of cell viability) (Sigma-Aldrich, St. Louis, MO) according to the protocol and guidelines provided by Barile (Barile

1994).

Statistical analysis

The experimental design used in all biological assays of this study was completely randomized. The mean of each treatment was compared to its respective control. Data were initially transformed to $\text{Log}(X)$, normalized, and then nonlinear regression was calculated to obtain IC_{50} (50% inhibition concentration) using the GraphPad Prism 7.0 software (Graph-Pad Inc., San Diego, CA, USA).

Results

This is the first study, the anti-*Ehrlichia* potential of *A. conyzoides* was calculated after 18h and 36h of treatment with the extract botanic (Fig 1). In the triplicate assays, the IC_{50} of the proposed treatment was $200 \mu\text{g.mL}^{-1}$.

Were assessed the viability of the DH82 cells against different concentrations of the tested treatment. Were noted that they were not toxic in the highest concentration, i.e. $500 \mu\text{g.mL}^{-1}$ (Fig 2) when compared with the control group which was formed by DH82 cells treated with ultrapure distilled water for only a 24-hour period.

In Fig. 3 shows the chromatogram of the extract dichloromethane of *A. conyzoides* with the UV absorption profiles of the 5 chromatographic peaks as evidenced by overlapping peaks high resolution in reverse phase (Table 1).

Lignans was the major class of the extract dichloromethane of *A. conyzoides* collected in São Luís, MA, northeast Brazil. This class of compounds was first identified in this specimen.

Discussion

To the best of the knowledge, this is the first study to report the anti-*Ehrlichia* activity of the botanical extract of *Ageratum conyzoides* L. Recently a scientific paper on the efficacy of *A. conyzoides* against bacteria *Ehrlichia canis* has been published, but the product used by the researchers was the essential oil (Rosario et al. 2019).

The DCM extract of this specimen showed remarkable anti-*Ehrlichia* activity at the concentration of $200 \mu\text{g.mL}^{-1}$ (Fig. 1). The botanical extract of *A. conyzoides* was active against intracellular microorganisms, such as *Trypanosoma brucei rhodesiense*, *Leishmania donovani* (Nour et al. 2010), and against *Plasmodium falciparum* (Owuor et al. 2012) as previously described in the literature by other authors. In addition, the efficacy of *A. conyzoides* extract against *Leishmania infantum* (Joshi et al. 2016) and *Leishmania amazonensis* (Teixeira et al. 2014) has been demonstrated by a number of researchers.

The chemical characterization of the dichloromethane extract of *A. conyzoides* obtained in this study shows that almost all of it is composed of secondary metabolites of the lignan class (Fig. 3). According to the literature, lignans has remarkable biological activities including their anti-*Leishmania* action (Royo et al. 2003) and trypanocidal action which results in mitochondrial dysfunction and oxidative damage which can trigger destructive effects on the biological molecules of these microorganisms leading to death (Bernardes et al. 2006; Izumi et al. 2011; Luize et al. 2006; Pelizzaro-Rocha et al. 2011).

The semi-synthetic derivatives of the lignans including (-) - quinoline, (-) - O-benzyl cubebin, and (-) - (N, N-dimethylaminoethyl) cubebene showed also antiprotozoal activity against amastigote stages of *T. cruzi* with IC₅₀ = 0.7; 5.7 and 4.7 μ m respectively, after 24 h of incubation (Souza et al. 2005). A number of studies have shown that lignan (-) - hinoquinine is effective in reducing chromosomal damage induced by doxorubicin as it has an antioxidant effect on the mitochondria of the parasite (Saraiva et al. 2007; Izumi et al. 2011). Syringaresinol likely compound found in the botanical extract (Table 1) has antitrypanosomal and anti-*Leishmania* activity (Costa et al. 2018) in addition to its antibacterial and antitrypanosomal activity (Alamzeb et al. 2013).

To date, the mechanism of action of plant lignans against *E. canis* is unknown. We suggest that these substances (polyphenols) inhibit the formation of microtubules, preventing cell division (Wink 2015) since the microtubules are responsible for the organization of the mitotic spindle. *Ehrlichia* replicates by binary fission and subsequently form elemental corpuscles which are seen as pleomorphic inclusions (initial corpuscles) inside leukocytes (Almosny et al. 2002).

The dichloromethane extract of *A. conyzoides* collected in São Luís, MA, northeast Brazil, has a promising lignan composition with remarkable anti-*Ehrlichia* activity, and may be a potential alternative treatment for one of the most important diseases of companion animals.

Declarations

Acknowledgments

The author CJRMR received scholarship from Coordenação de Aperfeiçoamento de Pessoal de Nível Superior CAPES (Coordination for the Improvement of High Higher Education Personnel, Brazil).

Authors' contributions

CJRMR and FAM designed the study. CJRMR, CQR, DMA, CAAL, DPBS, JACL, DFC and FAM carried out experiments and analyzed the data. CJRMR wrote the manuscript. All authors read and approved the final manuscript.

Author details

¹Laboratory of Immunodiagnosis, State University of Maranhão, São Luís, MA, Brazil. ²Laboratory of Advanced Studies in Phytomedicines, Department of Chemistry, Center for Exact Sciences and

Technology, Federal University of Maranhão, São Luís, MA, Brazil. ³Laboratory of Virology and Rickettsioses, Faculty of Veterinary Medicine, Federal University of Mato Grosso, Cuiabá, MT, Brazil. ⁴Laboratory of Pharmacognosy II, Department of Pharmacy, Federal University of Maranhão, São Luís, MA, Brazil.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

All data generated or analyzed during this study are included in this published article in the main manuscript and additional supporting file.

Consent to publish

Not applicable.

Ethics approval and consent to participate

Not applicable.

Funding

No funding source was received. The article is self funded by the authors. All authors shared in the design of the study, collection, analysis, and interpretation of data and in writing the manuscript.

References

1. Aguiar DM, Saito TB, Hagiwara MK, Machado RZ, Labruna MB (2007) Diagnóstico sorológico de erliquiose canina com antígeno brasileiro de *Ehrlichia canis*. Cienc rural 37(3): 796- 802. Available from: <http://www.scielo.br/pdf/cr/v37n3/a30v37n3.pdf>
2. Alamzeb M, Khan MR, Ali S, Mamoon-Ur-Rashid Khan AA (2013) Bioassay guided isolation and characterization of anti-microbial and anti-trypanosomal agents from *Berberis glaucocarpa* Stapf. Afr J Pharm Pharmacol 7 (29): 2065-2071. doi:10.5897/AJPP2013.3444
3. Almosny NRP, Massard CL (2002) Erliquiose. In: Hemoparasitoses em Pequenos Animais Domésticos e como Zoonoses. Almosny NRP, Rio de Janeiro, RJ
4. ANVISA (2010) Agência Nacional de Vigilância Sanitária. Farmacopeia Brasileira. Brasília, Brasil
5. Barile FA (1994) In vitro cytotoxicology. New York, USA
6. Bernardes LSC, Kato MJ, Albuquerque S, Carvalho I (2006) Synthesis and trypanocidal activity of 1,4-bis-(3,4,5-trimethoxy-phenyl)-1,4-butanediol and 1,4-bis-(3,4-dimethoxyphenyl)-1,4-butanediol. Bioorg. Med Chem 14(21): 7075-7082. doi:10.1016/j.bmc.2006.07.006

7. Bogićević N, Radovanović ME, Vasić A (2017) Seroprevalence of *Ehrlichia canis* infection in stray dogs from Serbia. *Mac Vet Rev* 40 (1): 37-42. Available from: <https://www.macvetrev.mk/2017-1/macvetrev-2016-0096.pdf>
8. Breitschwerdt EB. Riquetsioses (2004) In: Ettinger SJ, Feldman EC. *Tratado de medicina interna veterinária. Doenças do cão e do gato*. 5.ed. Rio de Janeiro: Guanabara Koogan
9. Cimanga RK, Munduku CK, Ehata MT, Lumpu SN, Maya MB, Manienga K, Bumoyi K, Kabangu OK (2014) Antibacterial and antifungal screening of extracts from six medicinal plants collected in Kinshasa-Democratic Republic of Congo against clinical isolate pathogens. *J Pharmacognosy and Phytother*. 6 (3): 24-32. doi: [10.5897/JPP2013.0263](https://doi.org/10.5897/JPP2013.0263)
10. Costa RS, Sousa Filho OP, Dias Júnior OCS, Silva JJ, Hyaric ML, Santos MAV, Velozo ES (2018) In vitro antileishmanial and antitrypanosomal activity of compounds isolated from the roots of *Zanthoxylum tingoassuiba* Rev. bras. farmacogn 28(5): 551-558. doi:[10.1016/j.bjp.2018.04.013](https://doi.org/10.1016/j.bjp.2018.04.013)
11. Cunha BA (2001) Antibiotic side effects. *Med Nort Am*. 85 (1): 149-85.
12. Dagnone AS, Morais HSA, Vidotto O (2001) Erliquiose nos animais e no homem. *Semina: Ci. Agrárias, Londrina* 22 (2): 191-201. Available from: <http://www.uel.br/revistas/uel/index.php/semagrarias/article/viewFile/2053/1762>
13. Damaso D (1990) *Tetraciclinas. Antibacterianos*. Madrid: Ed. Marketing Pharm SA
14. Donahue HJ, Iijima K, Goligorsky MS, Rubin CT, Rifkin BR (1992) Regulation of cytoplasmic calcium concentration in tetracycline- treated osteoclasts. *J Bone Miner Res* 7 (11): 1313-1318. doi:[10.1002/jbmr.5650071111](https://doi.org/10.1002/jbmr.5650071111)
15. González-Lamothe R, Mitchell G, Gattuso M, Diarra MS, Malouin F, Bouarab K (2009) Plant Antimicrobial Agents and Their Effects on Plant and Human Pathogens. *Int J Mol Sci* 10(8): 3400–3419. doi: [10.3390/ijms10083400](https://doi.org/10.3390/ijms10083400)
16. Goodman L, Gilman A (1990) *The pharmacological basis of therapeutics*. 8 ed. Pergamon. New York; pp. 1158-1175
17. Gugliemo J, Jacobs R (2001) *Agentes antiinfeciosos quimioterapicos e antibióticos. Diagnóstico & Tratamento*. São Paulo: Ed. Ateneu
18. Izumi E, Ueda-Nakamura T, Dias Filho BP, Veiga Júnior VF, Nakamura CV (2011) Natural products and Chagas' disease: a review of plant compounds studied for activity against *Trypanosoma cruzi*. *Nat Prod Rep* 28(4): 809-823. doi:[10.1039/c0np00069h](https://doi.org/10.1039/c0np00069h)
19. Joshi B, Hendrickx S, Magar LB, Parajuli N, Dorny P, Maes L (2016) In vitro antileishmanial and antimalarial activity of selected plants of Nepal. *J Intercult Ethnopharmacol* 5(4): 383–389. doi:[10.5455/jice.20160728031236](https://doi.org/10.5455/jice.20160728031236)
20. Kanyanga RC, Munduku CK, Ehata MT, Lumpu SN, Maya MB, Manienga K, Bumoyi K, Kabangu OK (2014) Antibacterial and antifungal screening of extracts from six medicinal plants collected in Kinshasa-Democratic Republic of Congo against clinical isolate pathogens. *J Pharmacognosy Phytother* 6(3): 24-32. doi: [10.5897/JPP2013.0263](https://doi.org/10.5897/JPP2013.0263)
21. Kissmann KG, Groth D (1999) *Plantas infestantes e nocivas*, 2ª ed., São Paulo: BASF A.S.

22. Luize PSL, Ueda-Nakamura T, Dias Filho BP, Diógenes AGC, Nakamura CV (2006) Activity of Neolignans Isolated from *Piper regnellii* (MIQ.) C. DC. var. *pallescens* (C. DC.) YUNCK against *Trypanosoma cruzi*. Biol Pharm Bull 29 (10): 2126-2130. doi:10.1248/bpb.29.2126
23. Mylonakis ME, Koutinas AF, Billinis C, Leontides LS, Kontos V, Papadopoulos O, Raillis T, Fytianou A (2003) Evaluation of citology in the diagnosis of acute canine monocytic ehrlichiosis (*Ehrlichia canis*): a comparison between five methods. Vet Microbiol 91 (2-3): 197- 204. doi:10.1016/S03781135(02)00298-5
24. Nour AMM, Khalid SA, Kaiser M, Brun R, Abdalla WE, Schmidt TJ (2010) The antiprotozoal activity of methylated flavonoids from *Ageratum conyzoides* L. J Ethnopharmacol 129(1): 127– 130. doi:10.1016/j.jep.2010.02.015
25. Owuor BO, Ochanda JO, Kokwaro JO, Cheruiyot AC, Yeda RA, Okudo CA, Akala HM (2012) In vitro antiplasmodial activity of selected Luo and Kuria medicinal plants. J Ethnopharmacol 144(3): 779– 781. doi:10.1016/j.jep.2012.09.045
26. Pelizzaro-Rocha KJ, Veiga-Santos P, Lazarin-Bidóia D, Ueda-Nakamura T, Dias Filho BP, Ximenes VF, Silva SO, Nakamura CV (2011) Trypanocidal action of eupomatenoid-5 is related to mitochondrion dysfunction and oxidative damage in *Trypanosoma cruzi*. Microb Infect 13(12-13): 1018-1024. doi: 10.1016/j.micinf.2011.05.011
27. Prajapati R, Roy S, Mishra S, Raza SK, Thakur LK (2014) Formulation development, standardization and antimicrobial activity of *Ageratum conyzoides* extracts and their formulation. Int J Pharm Pharm Sci 6 (2): 369-374. Available from: <http://connection.ebscohost.com/c/articles/95530798/formulation-development-standardization-antimicrobial-activity-ageratum-conyzoides-extracts-their-formulation>.
28. Rolain JM, Maurin M, Vestris G, Raoult D (1998) In vitro susceptibilities of 27 rickettsiae to 13 antimicrobials. Antimicrob Agents Chemother 42:1537– 1541. <https://doi.org/10.1128/AAC.42.7.1537>
29. Rolain JM, Stuhl L, Maurin M, Raoult D (2002) Evaluation of antibiotic susceptibilities of three rickettsial species including *Rickettsia felis* by a quantitative PCR DNA assay. Antimicrob Agents Chemother 46:2747–2751. <https://doi.org/10.1128/AAC.46.9.2747-2751.2002>
30. Rosário CJRM, Rocha CQ, Aguiar DM, Lima CAA, Silveira DPB, Leite JAC, Coutinho DF, Melo FA (2019) Anti-*Ehrlichia* properties of the essential oil of *Ageratum conyzoides* L. and its interaction with doxycycline. AMB Express Apr 29; 9(1):58. doi: 10.1186/s13568-019-0780-y
31. Royo VA, Filho AAS, Souza VA, Pereira AC, Silva R, Vinholis AHC, Donate PM, Silva MLA, Albuquerque S, Bastos JK (2003) Biological activity evaluation of dibenzilbutirolactones lignans derivatives against *Leishmania brasiliensis*. Rev bras farmacogn 13 (2): 18-21. <http://dx.doi.org/10.1590/S0102695X2003000400007>
32. Samy RP, Manikandan J, Al Qahtano M (2013) Evaluation of aromatic plants and compounds used to fight multidrug resistant infections. Evid Based Complement Alternat Med Medicine. Article ID 525613, 17 pages. <http://dx.doi.org/10.1155/2013/525613>

33. Saraiva J, Veja C, Rolon M, Silva R, Silva MLA, Donate PM, Bastos JK, Gomez-Barrio A, Albuquerque S (2007) In vitro and in vivo activity of lignan lactones derivatives against *Trypanosoma cruzi*, *Parasitol Res* 100 (4): 791-795. doi: [10.1007/s00436-006-0327-4](https://doi.org/10.1007/s00436-006-0327-4)
34. Saucedo R. (2003). Tetraciclina. Farmacocinética. Universidad de Granada, 2003. Available from: <http://www.ugr.es/~morillas/temas/tetracic/sld003.htm>
35. Singh BR, VOR Kumar, Sinha DK, RK Agrawal, Vadhana P, Bharadwaj M, Singh SV (2016). Antimicrobial Activity of Methanolic Extract and Ether Extract of *Ageratum conyzoides*. *Pharm Anal Acta*. 7: 471. doi: 10.4172/2153-2435.1000471
36. Sousa VRF, Almeida ABPF, Barros LA, Sales, KG, Justino, CHS, Dalcin, L, Bomfim TCB (2010) Avaliação clínica e molecular de cães com erliquiose. *Ciênc rural* 40 (6): 1309-1313.
37. Souza VA, Silva R, Pereira AC, Royo VA, Saraiva J, Montanheiro M, Souza GHB, Silva-Filho AA, Grando MD, Donate PM, Bastos JK, Albuquerque S, Silva MLA (2005) Trypanocidal activity of (-)-cubebin derivatives against free amastigote forms of *Trypanosoma cruzi*. *Bioorg Med Chem Lett* 15(2): 303-307. doi:[10.1016/j.bmcl.2004.10.079](https://doi.org/10.1016/j.bmcl.2004.10.079)
38. Teixeira TL, Teixeira SC, Silva CV, Souza MA (2014) Potential therapeutic use of herbal extracts in trypanosomiasis. *Pathog Glob Health* 108(1): 30-36. doi:[10.1179/2047773213Y.0000000120](https://doi.org/10.1179/2047773213Y.0000000120)
39. Tilley LP, Smith Junior, Francis WK (2003) Consulta veterinária em 5 minutos. 2. ed. Barueri: Manole, 2003.
40. Torres ME (2000) Tetraciclina. Propriedades farmacocinéticas. *Infecto*, 2000. Available from: <http://www.infecto.edu.uy/terapeutica/atbfa/tetra/framec.html>
41. Van Linthoudt D, Francois R, Ott H (1991) Contribution to the study of tetracycline bone side-effects. Absence of calcium deposition impairment in the trabecular bone of a patient treated during 3.5 years with doxycycline. *Z Rheumatol* 50 (3): 171-174.
42. Varela AS (2003) Tick-borne Ehrlichiae and Rickettsiae of dogs. In: Bowman DD. Companion and exotic animal parasitology. 2003. Available from: <https://pdfs.semanticscholar.org/8676/9120ddd537819275b105f7fbf1650e5689c0.pdf>
43. Waner T, Harrus S (2000) Canine monocytic ehrlichiosis (CME). In: _____. Recent advances in canine infectious disease. 13 apr 2000. Available from: <https://pdfs.semanticscholar.org/b19e/15c84a975bac851dfce84c3d4c13ed74737f.pdf>
44. Wink M (2015) Modes of Action of Herbal Medicines and Plant Secondary Metabolites. *Medicines* 2, 251-286. doi:[10.3390/medicines2030251](https://doi.org/10.3390/medicines2030251)
45. Workowski KAA (2002) Sexually transmitted diseases treatment Guidelines. *MMWR Morb Mortal Wkly Rep*. 51 (RR-6):1. Available from: <https://www.cdc.gov/mmwr/pdf/rr/rr6403.pdf>
46. Zimmerman HJ. (2000). Drug-induced liver disease. *Clin Liver Dis*. 4(1): 73-96.

Table

Table 1: Identification of compounds in *Ageratum conyzoides* dichloromethane extract by LC-ESI-IT/MS.

Peaks	[M-H] ⁻	Ms ⁿ	Proposed compound
1	175	159; 145; 132; 115	Hydroxy methyl coumarin
2	417	402;387;372;356;328;300	Syringaresinol
3	403	390; 345	Derived from syringaresinol 1
4	431	415; 400;369	Derived from syringaresinol 2
5	387	372; 356; 341; 313; 285	Derived from syringaresinol 3

Figures




Figure 1

Percentage of inhibition of *Ehrlichia canis* in DH82 cells after 18h and 36h of treatment with the *A. conyzoides* DCM extract and with doxycycline (control group) at different concentrations. Each row represents mean and standard deviation of three independent assays in which * $p < 0.05$ demonstrated that there was no statistically significant difference in relation to the control group according to the Tukey-test with a 95% confidence index.




Figure 2

Each row represents mean and standard deviation of three independent assays. Where $*p < 0.05$ demonstrated that there was no statistically significant difference in relation to the control group according to the unpaired Student's t-test with a 95% confidence index.




Figure 3

HPLC-UV chromatogram (254 nm) of *Ageratum conyzoides* dichloromethane extract.